Biotechnology News and Research

RSS

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Astro Pak announces the launch of new subsidiary, SixLog

Astro Pak Corporation, the U.S.'s largest precision cleaning and passivation company, today announced the launch of their new subsidiary, SixLog Corporation. SixLog provides on-site biological decontamination services utilizing proprietary iHP™ (ionized Hydrogen Peroxide) technology to a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities.

12 Jan 2010

Madison Williams launches Healthcare Investment Banking and Research business

Madison Williams and Company, an integrated capital markets and advisory firm, announced today the formal launch of a focused Healthcare Investment Banking and Research business. Madison Williams recently completed a management buyout of the principal capital markets business from Sanders Morris Harris Group in December 2009. The new firm already has a leading franchise in the Energy sector, and is quickly establishing its presence in healthcare with key new hires.

12 Jan 2010

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

QIAGEN N.V. today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

From QIAGEN Manchester Limited 12 Jan 2010

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Paragon Biomedical, Inc. announced today that it has launched the second phase of its restructuring and growth plan for worldwide operations. Gena Reed, Paragon's Founder and Chief Executive Officer, said the strategy will build upon the company's strengths in its key therapeutic areas and regions.

12 Jan 2010

Pharmaron Holdings acquires Bridge Laboratories China

Pharmaron Holdings Limited, today announced it completed the acquisition of Bridge Laboratories China. Bridge Laboratories China is the leading contract research organization (CRO) in China providing western standard GLP-compliant toxicology services to pharmaceutical and biotech companies from around the world. With this acquisition, Pharmaron becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. This strategic acquisition strengthens Pharmaron's leading position in the fast-growing, highly dynamic pharmaceutical CRO industry.

12 Jan 2010

Public awareness campaign needed to curb health threats posed by hepatitis B and hepatitis C

Stepped-up vaccination requirements, a boost in resources for prevention and treatment, and a public awareness campaign similar to the effort that dispelled the stigma of HIV/AIDS are needed to curb the health threats posed by hepatitis B and hepatitis C, says a new report from the Institute of Medicine.

12 Jan 2010

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.

12 Jan 2010

BioCryst Pharmaceuticals signs agreements with two additional partners

BioCryst Pharmaceuticals, Inc. today announced that it has signed agreements with two additional partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities for territories outside of the U.S. BioCryst's new partners are Merck Serono for Europe, Russia, Canada and Singapore and Hikma Pharmaceuticals PLC for the Middle East and North Africa (MENA) region, excluding Israel.

12 Jan 2010

Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported

Pluristem Therapeutics Inc. today announced interim results from their Phase I clinical trials utilizing their placenta derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

12 Jan 2010

Illumina launches HumanOmniExpress BeadChip for GWAS

Illumina, Inc. today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

From Illumina, Inc. 11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

WuXi AppTec enters into partnership with QIAGEN

WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases.

From QIAGEN Manchester Limited 11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Quidel to acquire Diagnostic Hybrids for $130M

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today the signing of a definitive agreement to acquire privately held Diagnostic Hybrids, Inc. for approximately $130 million in cash.

10 Jan 2010

Biotechnology News and Research

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

miRagen Therapeutics establishes SAB

VentiRx Pharmaceuticals completes $25 million Series A Extension

Astro Pak announces the launch of new subsidiary, SixLog

Madison Williams launches Healthcare Investment Banking and Research business

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Millipore introduces new Viresolve Pro+ Solution

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Pharmaron Holdings acquires Bridge Laboratories China

Public awareness campaign needed to curb health threats posed by hepatitis B and hepatitis C

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

BioCryst Pharmaceuticals signs agreements with two additional partners

Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported

Illumina launches HumanOmniExpress BeadChip for GWAS

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

WuXi AppTec enters into partnership with QIAGEN

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Quidel to acquire Diagnostic Hybrids for $130M

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News